NovaBridge Biosciences cotiza a 1.29 USD y tiene una capitalización bursátil de $150M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody,…
| Periodo | 2026-08 | 2026-04 | 2025-12 | 2025-08 |
|---|---|---|---|---|
| Real | — | $-0.31 | $-0.06 | $-0.07 |
| Estimado | $-0.23 | $-0.08 | $-0.05 | $-0.12 |
| Sorpresa | — | -287.5% | -20.0% | +41.7% |
| Métrica | NBP | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -20.0% | -40.4% | +20.4% |
| ROA | -17.8% | -32.0% | +14.2% |
| Current Ratio | 8.09 | 2.84 | +5.25 |
| Debt / Equity | — | 0.28 | — |